A board-linked hedge fund manager at CVS filed to offload over $320 million in shares last week. Lawrence Robbins, who represents a hedge fund on the CVS board, filed sales of roughly 3.2 million shares between May 19–21, at prices near $94. Director Fernando Aguirre added another $2.9 million in sales on May 20.
The exits come as CVS trades near multi-year highs after a recovery run in healthcare stocks.
On the buying side, two institutional insiders piled into WGS — GeneDx Holdings. Casdin Capital and Corvex Management, both board-represented funds, collectively filed over $35 million in purchases between May 13–20. Casdin alone bought 500,000 shares across three days, averaging around $43. The cluster of buying across multiple insiders signals strong conviction in the genomics firm.
DKNG co-founder Matt Kalish filed the sale of 1.9 million shares on May 15 for $31.7 million at roughly $16.59 per share. Meanwhile, ARM Holdings saw its Chief Legal Officer Spencer Collins file sales totalling over $8.3 million earlier this month, with a second CLO filing an additional $2.4 million exit on May 21.
This article is not financial advice.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
